Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines, singly and in combination
Abstract
A double-blind, placebo-controlled comparison of single component and combination measles, mumps, and rubella (HPV-77:DE-5 and RA 27/3) virus vaccines involving 502 young children was conducted. The rubella antibody response was similar with RA 27/3 rubella and measles-mumps-rubella (RA 27/3) vaccines, but was diminished with the combination vaccine that incorporated HPV-77:DE-5 rubella. There was no evidence of enhanced clinical reactivity with either of the measles-mumps-rubella vaccines.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Out of the five RCTs and one CCT assessing short-term side effects, only two studies (Lerman 1981; Peltola 1986) had adequate concealment.
“Out of the five RCTs and one CCT assessing short-term side effects, only two studies (Lerman 1981; Peltola 1986) had adequate concealment.”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as Lerman 1981
Lerman 1981 concluded there was no increased clinical reactivity with an MMR vaccine containing two strains of rubella.
“Another trial concluded that there was no increased clinical reactivity with a MMR vaccine containing two strains of rubella (Lerman 1981).”
From Vaccines for measles, mumps and rubella in children (2012) · cites this paper as Lerman 1981
Cited by
Sorted by citations
Hviid, A. P., Rubin, S. A., & Mühlemann, K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60419-5 · Cited by 537 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Di Pietrantonj, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub3 · Cited by 372 · see citing works
Peltola, H., Heinonen, O. P., Valle, M., Paunio, M., Virtanen, M., Karanko, V., & Cantell, K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312101 · Cited by 344 · see citing works
FREQUENCY OF TRUE ADVERSE REACTIONS TO MEASLES-MUMPS-RUBELLA VACCINE
Peltola, H., & Heinonen, O. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91044-5 · Cited by 212 · see citing works
Vaccines for measles, mumps, rubella, and varicella in children
Pietrantonj, C. D., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub4 · Cited by 197 · see citing works
Benefits, risks and costs of immunization for measles, mumps and rubella.
White, C. C., Koplan, J. P., & Orenstein, W. A. (1985) · American Journal of Public Health · doi:10.2105/ajph.75.7.739 · Cited by 193 · see citing works
Robertson, S., Cutts, F., Samuel, R., et al. (1997) · PubMed · Cited by 176 · see citing works
Halsey, N. A., Hyman, S. L., & Panel, T. C. W. (2001) · PEDIATRICS · doi:10.1542/peds.107.5.e84 · Cited by 154 · see citing works
Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination
Virtanen, M., Peltola, H., Paunio, M., & Heinonen, O. P. (2000) · PEDIATRICS · doi:10.1542/peds.106.5.e62 · Cited by 105 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Jefferson, T., Rivetti, A., & Price, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub2 · Cited by 104 · see citing works
Unintended events following immunization with MMR: a systematic review
Jefferson, T., Price, D., Demicheli, V., & Bianco, E. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00271-8 · Cited by 86 · see citing works
“We classified two trials as at low risk of bias [19,26], two [16,18] at moderate risk and two [1,25] at high risk of bias (Table 1).”
BackgroundMethodInfluentialVaccine safety issues at the turn of the 21st century
Conklin, L. M., Hviid, A. P., Orenstein, W. A., Pollard, A. J., Wharton, M. E., & ZUBER, P. L. F. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-004898 · Cited by 64 · see citing works
“61 Randomised controlled trials and epidemiological studies of MMR vaccine have shown similar immunological responses, whether given singly or in combination with other vaccines, and no increased risk of invasive bacterial infection up to 90 days after immunisation was found.”
BackgroundMethodVaccines for measles, mumps, rubella, and varicella in children
Pietrantonj, C. D., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004407.pub5 · Cited by 100 · see citing works
Zimmerman, R. K., Bradford, B. J., Janosky, J. E., Mieczkowski, T. A., DeSensi, E. G., & Grufferman, S. (1997) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)30204-6 · Cited by 57 · see citing works
Vaccines for measles, mumps and rubella in children
Demicheli, V., Rivetti, A., Debalini, M. G., & Pietrantonj, C. D. (2013) · Evidence-Based Child Health A Cochrane Review Journal · doi:10.1002/ebch.1948 · Cited by 51 · see citing works
Makino, S. (1990) · American Journal of Diseases of Children · doi:10.1001/archpedi.1990.02150320069030 · Cited by 47 · see citing works
Markowitz, L. E., & Orenstein, W. A. (1990) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)36907-3 · Cited by 45 · see citing works
Combination Vaccines: Defining and Addressing Current Safety Concerns
Halsey, N. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322567 · Cited by 41 · see citing works
“The rates of fever, rash, or both in the 3 weeks after MMR vaccination are similar to the rates when measles vaccine alone is administered; the inclusion of rubella vaccine adds a variable incidence of arthralgia, depending on the age and sex of the vaccinee [10, 11].”
Adverse events following measles—mumps—rubella and measles vaccinations in college students
Chen, R. T., Moses, J. M., Markowitz, L. E., et al. (1991) · Vaccine · doi:10.1016/0264-410x(91)90053-9 · Cited by 40 · see citing works
Strebel, P. M., Papania, M. J., Dayan, G. H., & Halsey, N. A. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50022-2 · Cited by 132 · see citing works
Serological evaluation of a measles, mumps, and rubella vaccine
Robertson, C. M., Bennett, V. J., Jefferson, N., & Mayon-White, R. T. (1988) · Archives of Disease in Childhood · doi:10.1136/adc.63.6.612 · Cited by 34 · see citing works
“16 This trial confirms this for the measles part of the Merieux vaccine.”
BackgroundZimmerman, R. K., Giebink, G. S., Street, H., et al. (1995) · PubMed · Cited by 34 · see citing works
Strebel, P. M., Papania, M. J., Gastañaduy, P. A., & Goodson, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00037-7 · Cited by 55 · see citing works
Physician Concerns About Vaccine Adverse Effects and Potential Litigation
Zimmerman, R. K., Schlesselman, J. J., Mieczkowski, T. A., Medsger, A. R., & Raymund, M. (1998) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.152.1.12 · Cited by 32 · see citing works
“7% of recipients.(23) Many physicians who believe that adverse effects from DTP are likely were highly concerned about litigation from injuries allegedly related to vaccination.”
Measles, mumps, rubella, and varicella
Isaacs, D., & Menser, M. A. (1990) · The Lancet · doi:10.1016/0140-6736(90)91255-9 · Cited by 32 · see citing works
Strebel, P. M., Papania, M. J., Fiebelkorn, A. P., & Halsey, N. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00028-8 · Cited by 31 · see citing works
Optimal age for measles and mumps vaccination in Australia
Kakakios, A. M., Burgess, M. A., Bransby, R. D., et al. (1990) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1990.tb125306.x · Cited by 28 · see citing works
Kuter, B. J., Brown, M. L. H., Wiedmann, R. T., Hartzel, J. S., & Musey, L. K. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001241 · Cited by 24 · see citing works
“M-M-RII (measles, mumps and rubella virus vaccine live, West Point, PA), a trivalent vaccine with an improved safety and immunogenicity profile prepared with the RA 27/3 rubella strain, was licensed in 1978.(6,7) M-M-RII has been used in many countries around the world for many years and has been the only combination…”
MethodResultInfluentialComparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
Yadav, S., Thukral, R., & Chakarvarti, A. (2003) · PubMed · Cited by 25 · see citing works
Combined and Simultaneously Administered Vaccines
Parkman, P. D. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44431.x · Cited by 25 · see citing works
McLean, H. Q., Fiebelkorn, A. P., Ogee-Nwankwo, A., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.010 · Cited by 24 · see citing works
Plotkin, S. A., & Rubin, S. A. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50024-6 · Cited by 24 · see citing works
Plotkin, S. A., & Reef, S. E. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50033-7 · Cited by 23 · see citing works
Two Doses of MMR Vaccine—Sufficient to Eradicate Measles, Mumps and Rubella?
Fahlgren, K. (1988) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488801600301 · Cited by 23 · see citing works
Tapiainen, T., & Heininger, U. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.3.419 · Cited by 22 · see citing works
Rubin, S. A., & Plotkin, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00007-0 · Cited by 22 · see citing works
Adverse reactions associated with simultaneous administration of multiple vaccines to travelers
Falvo, C., & Horowitz, H. W. (1994) · Journal of General Internal Medicine · doi:10.1007/bf02599650 · Cited by 21 · see citing works
ORIGINAL ARTICLE: Vaccination of children – a systematic review
Örtqvist, A. K., Blennow, M., Carlsson, R. M., La, H., Lindberg, A., LINDQVIST, L., Magnusson, M., Nilsson, L. J., Norlund, A., Nyrén, O., et al. (2010) · Acta Paediatrica · doi:10.1111/j.1651-2227.2010.01823.x · Cited by 20 · see citing works
Evolving pharmacovigilance requirements with novel vaccines and vaccine components
ZUBER, P. L. F., Gruber, M. F., Kaslow, D. C., et al. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2020-003403 · Cited by 20 · see citing works
“46 A quadrivalent live influenza vaccine was, however, found to have lower efficacy than non-live preparations.”
BackgroundPrevention of measles, mumps and rubella: 40 years of global experience with M-M-R II
Kuter, B. J., Marshall, G. S., FERGIE, J. E., Schmidt, E., & Pawaskar, M. D. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2007710 · Cited by 17 · see citing works
Reef, S. E., & Plotkin, S. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00038-0 · Cited by 16 · see citing works
Reef, S. E., & Plotkin, S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00052-3 · Cited by 13 · see citing works
Nakayama, T., Urano, T., Osano, M., Nakagawa, M., Maehara, N., Sasaki, K., Yamamura, A. M. Y., & Makino, S. (1990) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1990.tb03167.x · Cited by 13 · see citing works
Perelygina, L. M., Adebayo, A., Metcalfe, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133267 · Cited by 12 · see citing works
Ledogar, R. J., Fleming, J. R., & Andersson, N. (2009) · BMC International Health and Human Rights · doi:10.1186/1472-698x-9-s1-s6 · Cited by 11 · see citing works
“Of 31 studies that met the Cochrane review’s inclusion criteria, we selected those 20 that contained specific numbers of adverse effect cases together with the total study population [13-32].”
MMR vaccine - how effective and how safe?
(2003) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2003.41425 · Cited by 10 · see citing works
Adcock, L. M., Bissey, J. D., & Feigin, R. D. (1992) · PubMed · Cited by 10 · see citing works
Dennehy, P. H., Jaeger, J. L., Losikoff, P. T., & Pugatch, D. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50260-0 · Cited by 7 · see citing works
Adcock, L. M., Bissey, J. D., & Feigin, R. D. (1992) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30429-3 · Cited by 8 · see citing works
Measles, Mumps and Rubella Vaccine
West, R., & Roberts‐Miller, P. (1999) · BioDrugs · doi:10.2165/00063030-199912060-00002 · Cited by 7 · see citing works
Moss, W. J., & Strebel, P. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00038-4 · Cited by 6 · see citing works
Wrong About Vaccine Safety: A Review of Andrew Wakefield’s “Callous Disregard”
Harrison, J. A. (2013) · The Open Vaccine Journal · doi:10.2174/1875035420131126002 · Cited by 6 · see citing works
Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine)
Nyaku, M. K., Richardson, E., Martinón‐Torres, F., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003273 · Cited by 5 · see citing works
“), which was the first combination MMR vaccine licensed in the United States using the HPV77:DE-5 rubella strain.(4,5) M-M-RII has been used in many countries for over 40 years with more than 803 million doses distributed worldwide (Merck & Co.”
MethodAustralian Population Cohort Study of Newly Arrived Refugee Children
Joshua, P., Smith, M. M., Koh, A. S. K., et al. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31827075c2 · Cited by 5 · see citing works
CHILDHOOD IMMUNIZATION GUIDELINES: CURRENT AND FUTURE
Zimmerman, R. K., & Burns, I. T. (1994) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(21)00486-3 · Cited by 4 · see citing works
Vaccins associes et seroconversions
Fillastre, C., & Guerin, N. (1987) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(87)80099-9 · Cited by 3 · see citing works
Conventional and New Generation Combined Vaccines
André, F. E., Stanbury, W. J., & Teuwen, D. E. (1994) · Springer eBooks · doi:10.1007/978-1-4899-1450-7_4 · Cited by 2 · see citing works
Pediatric Combination Vaccines
Vidor, E. J., Hoffenbach, A., & Plotkin, S. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-265-4_1 · Cited by 2 · see citing works
The Measles–Mumps–Rubella Vaccination Program in Finland
Redd, S. C., Wharton, M. E., Hadler, S. C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504203321615 · Cited by 2 · see citing works
The Ongoing Search for Balance: An Evolving Adolescent Health Service.
Bennett, D. (1985) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh.1985.1.1-2.167
Measles-Mumps-Rubella Vaccination Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of
Virtanen, M., Peltola, H., Paunio, M., et al. (2012)
Reef, S. E., & Plotkin, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00054-2
- Authors
- Lerman, S. J., Bollinger, M., & Brunken, J. M.
- Affiliations
- University of Nebraska Medical Center (US)
- Venue
- PEDIATRICS
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 1981-07-01
- Volume
- 68
- Issue
- 1
- Pages
- 18-22
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W1532587019
- Cited by
- 62
- References
- 0
- Citations by year
- 2023: 2 · 2021: 5 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2013: 5 · 2012: 3
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PEDIATRICS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- MMR vaccine, vaccine safety, young children
- MeSH terms
- Antibodies, Viral, Child, Clinical Trials as Topic, Double-Blind Method, Humans, Measles Vaccine, Mumps Vaccine, Rubella Vaccine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
